• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Senti Biosciences Inc.

    4/30/25 4:28:45 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SNTI alert in real time by email
    DEFA14A 1 a20250430defa14a.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A INFORMATION
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934 (Amendment No.____)
    Filed by the Registrant x
    Filed by a Party other than the Registrant o
    Check the appropriate box:
    oPreliminary Proxy Statement
    oConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    oDefinitive Proxy Statement
    xDefinitive Additional Materials
    oSoliciting Material under §240.14a-12
    SENTI BIOSCIENCES, INC.
    (Name of registrant as specified in its charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    xNo fee required.
    oFee paid previously with preliminary materials;
    oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11






    additionalmaterial1.gif



    additionalmaterial2.gif

    Get the next $SNTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNTI

    DatePrice TargetRatingAnalyst
    6/6/2025$5.00Buy
    Laidlaw
    10/7/2022$7.50Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SNTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Senti Biosciences Announces New Employment Inducement Grants

      SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on June 3, 2025 Senti Bio's Board of Directors granted to eight new employees stock options to purchase an aggregate of 102,500 shares of the Company's common stock with a per share exercise price of $3.03. These awards were made under the Company's Amended and Restated 2022 Inducement Equity Plan (the "Plan"). The above-described awards were each granted as an inducement material to the employees entering into employment

      6/9/25 4:30:00 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

      SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will participate in a Virtual Fireside Chat hosted by Chardan Capital Markets, LLC on Monday, June 9, 2025 at 3:00 PM ET. For the fireside chat, Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer, Kanya Rajangam, M.D., Ph.D. President, Head of Research & Development and Chief Medical Officer, and Jay Cross, Chief Financial Officer of Senti Biosciences will join Chardan senior research analy

      6/6/25 9:05:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

      SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer of Senti Bio, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025 at 2:40 PM ET. Conference Details: Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar Date/Time: Thursday, May 29th at 2:40 PM ET Presenter: Timothy Lu, M.D., Ph.D. Co-Founder and Chi

      5/22/25 4:05:55 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Senti Biosciences Inc.

      SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

      5/15/25 4:43:33 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Senti Biosciences Inc.

      SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

      5/15/25 4:41:42 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Senti Biosciences Inc.

      SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

      5/15/25 4:36:10 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Laidlaw initiated coverage on Senti Bio with a new price target

      Laidlaw initiated coverage of Senti Bio with a rating of Buy and set a new price target of $5.00

      6/6/25 8:36:59 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley initiated coverage on Senti Bio with a new price target

      Morgan Stanley initiated coverage of Senti Bio with a rating of Equal-Weight and set a new price target of $7.50

      10/7/22 7:14:34 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SNTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Celadon Partners Spv 24 converted options into 9,777,000 shares (SEC Form 4)

      4 - Senti Biosciences, Inc. (0001854270) (Issuer)

      3/14/25 11:52:40 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Celadon Partners Spv 24

      3 - Senti Biosciences, Inc. (0001854270) (Issuer)

      3/13/25 4:32:52 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner New Enterprise Associates 15, L.P. converted options into 3,333,000 shares (SEC Form 4)

      4 - Senti Biosciences, Inc. (0001854270) (Issuer)

      3/12/25 9:30:38 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care